Categories AlphaGraphs, Earnings, Health Care
Infographic: Key highlights from Biogen (BIIB) Q2 2022 earnings results
Biogen Inc. (NASDAQ: BIIB) reported second quarter 2022 earnings results today.
Total revenue decreased 7% year-over-year to $2.58 billion.
Net income attributable to Biogen Inc. was $1 billion, or $7.24 per share, compared to $448.5 million, or $2.99 per share, last year. Adjusted EPS was $5.25.
Biogen raised its revenue and adjusted EPS guidance for the full year of 2022 based on better-than-expected topline performance and continued cost management. For FY2022, revenue is now expected to be $9.9-10.1 billion and adjusted EPS is now expected to be $15.25-16.75 compared to the previous ranges of $9.7-10 billion for revenue and $14.25-16.00 for adjusted EPS.
Prior performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
